Financial Evaluation of Kidney Transplant With Hepatitis C Viremic Donors to Uninfected Recipients

Kidney transplantation with hepatitis C viremic (dHCV+) donors appears safe for recipients without HCV when accompanied by direct acting antiviral (DAA) treatment. However, US programs have been reluctant to embrace this approach due to concern about insurance coverage. While the cost of DAA treatme...

Descripción completa

Detalles Bibliográficos
Autores principales: Axelrod, David A., Lentine, Krista L., Balakrishnan, Ramji, Chang, Su-Hsin, Alhamad, Terek, Xiao, Huiling, Kasiske, Bertran L., Bloom, Roy D., Schnitzler, Mark A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Kidney Transplantation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665247/
https://www.ncbi.nlm.nih.gov/pubmed/33204825
http://dx.doi.org/10.1097/TXD.0000000000001056

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665247/
https://www.ncbi.nlm.nih.gov/pubmed/33204825
http://dx.doi.org/10.1097/TXD.0000000000001056

Ejemplares similares